PVLA Insider Trading

Palvella Therapeutics, Inc. (PVLA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.23B, listed on NASDAQ, employing roughly 29 people, carrying a beta of -0.17 to the broader market. Palvella Therapeutics, Inc. Led by Wesley H. Kaupinen, public since 2015-01-02.

In the last 12 months, Palvella Therapeutics, Inc. insiders made 3 buy transactions and 76 sale transactions.

DateNameTypeSharesPriceValue
Nov 12, 2026Martini Jeffrey SM-Exempt1,984$9.79$19.4K
Nov 12, 2026Martini Jeffrey SM-Exempt6,250$9.79$61.2K
Nov 12, 2026Martini Jeffrey SM-Exempt4,266$7.53$32.1K
Nov 12, 2026Martini Jeffrey SM-Exempt6,250$9.79$61.2K
Nov 12, 2026Martini Jeffrey SS-Sale100$163.34$16.3K
Nov 12, 2026Martini Jeffrey SS-Sale1,449$164.85$238.9K
Nov 12, 2026Martini Jeffrey SS-Sale1,650$164.14$270.8K
Nov 12, 2026Martini Jeffrey SM-Exempt4,266$7.53$32.1K
Nov 12, 2026Martini Jeffrey SS-Sale1,467$165.78$243.2K
Nov 12, 2026Martini Jeffrey SS-Sale1,651$165.85$273.8K

PVLA Insider Activity by Quarter

Reported Form 4 and Form 5 lines under PVLA's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A33$6.2M9
Q3 20260N/A22$6.2M14
Q2 20260N/A11$1.5M22
Q1 20263$850.0K7$1.3M17
Q4 20250N/A3$786.0K8
Q3 20250N/A0N/A0
Q2 20252$100.8K0N/A7
Q1 20250N/A0N/A10
Q4 20241$51.7K0N/A12

PVLA Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 197 institutions reported holding 14,091,679 PVLA shares, valued at $2.15B as reported, 110.7% of its market cap (market cap of Jun 26, 2026). That is +17 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 35 opened a position, 18 closed one, 89 added and 43 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
MONTANOVA CAPITAL, LLC1,135,406$173.5M-18,090
JENNISON ASSOCIATES LLC960,619$146.8M+320,008
BlackRock, Inc.918,357$140.3M+231,504
Frazier Life Sciences Management, L.P.882,400$134.8MUnchanged
First Light Asset Management, LLC771,901$118.0M-208,857
BVF INC/IL672,789$102.8M-288,200
STATE STREET CORP653,172$99.8M+194,173
PRICE T ROWE ASSOCIATES INC /MD/638,868$97.6M+236,304
VANGUARD CAPITAL MANAGEMENT LLC513,794$78.5M+36,500
FRONTIER CAPITAL MANAGEMENT CO LLC478,833$73.2M+104,798

By Quarter

QuarterInstitutionsSharesValue
Q2 202619714,091,679$2.15B
Q1 202618013,260,055$1.65B
Q4 20251409,759,635$1.02B
Q3 20251008,529,826$534.7M
Q2 2025655,909,749$133.2M
Q1 2025415,123,399$143.4M
Q4 2024334,033,115$48.4M

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding PVLA

FundWeight of PVLAShares (as reported)Value (as reported)Source updated
XBI State Street SPDR S&P Biotech ETF0.58%382,608$62.7MNov 12, 2026
VTI Vanguard Morningstar Total Stock Market ETF0.00%390,503$53.9MNov 12, 2026
IWM iShares Russell 2000 ETF0.06%307,952$50.5MNov 12, 2026
VXF Vanguard Extended Market ETF0.02%138,361$19.1MNov 12, 2026
IWO iShares Russell 2000 Growth ETF0.13%112,694$18.5MNov 12, 2026
SCHA Schwab U.S. Small-Cap ETF0.05%65,606$10.1MNov 13, 2026
VTWO Vanguard Russell 2000 ETF0.05%69,220$9.5MNov 12, 2026
VHT Vanguard Health Care ETF0.02%31,786$4.4MNov 12, 2026
PTH Invesco Dorsey Wright Healthcare Momentum ETF1.38%24,703$4.0MNov 12, 2026
DWAS Invesco Dorsey Wright SmallCap Momentum ETF0.92%22,377$3.7MNov 12, 2026
ITOT iShares Core S&P Total U.S. Stock Market ETF0.00%17,229$2.8MNov 12, 2026
VFMO Vanguard U.S. Momentum Factor ETF0.14%20,230$2.8MNov 12, 2026
SBIO ALPS Medical Breakthroughs ETF1.44%17,647$2.7MNov 13, 2026
LABU Direxion Daily S&P Biotech Bull 3X Shares0.11%13,888$2.3MNov 13, 2026
VTWG Vanguard Russell 2000 Growth ETF0.11%12,973$1.8MNov 12, 2026

From each fund's latest holdings file on record that shows PVLA's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as PVLA's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for PVLA reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is PVLA's share of that fund.

How to Read PVLA Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 76 sales versus 3 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked PVLA insider trading questions

How active are PVLA insiders right now?
Over the trailing twelve months, Palvella Therapeutics, Inc. (PVLA) insiders made 3 buy transactions and 76 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (76 sales vs 3 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are PVLA insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do PVLA insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.